SAMSUNG-ELECTRONICS-CO.
10.10.2019 12:02:06 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today unveiled an expanded portfolio of cutting-edge foundry solutions at its Samsung Foundry Forum (SFF) 2019 Munich.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005312/en/
Samsung attracted more than 200 industry experts from fabless companies and foundry partners, and 16 partner booths displayed advanced foundry technology trends, a significant increase in both numbers compared to last year, representing a more solid customer base of Samsung Foundry as well as greater collaboration in Europe, Middle East, and Africa (EMEA).
Since the EMEA semiconductor market is in demand across a wide range of applications including automotive, consumer, network, and internet-of things (IoT), Samsung introduced various specialty technologies, such as FD-SOI, radio frequency (RF), and embedded memory along with comprehensive portfolio of foundry process nodes.
Samsung Electronics showcased its state-of-the-art foundry platforms that bring together essential technical elements for new-age applications, including 5G, IoT, automotive, and high performance computing (HPC), while expanding its design solution partners to improve global customers' access to Samsung's foundry solutions.
"It is a great honor to host our global foundry forum with increasing number of attendees every year. The forum has helped us work closely with our customers and strengthen Samsung's foundry ecosystem," said Dr. ES Jung, president and head of foundry business at Samsung Electronics, in the keynote speech. "We will strive to get more customer' trust and be the best partner possible to prepare for the future with."
Given the robustness of the European automotive industry, the foundry platform for automotive semiconductor market is drawing considerable attention, and is expected to rapidly grow to address the increasing demand in the autonomous and electric vehicle market.
Samsung is currently producing several automotive semiconductor products such as driving assistant and infotainment systems, mainly based on its 28-nanometer (nm) FD-SOI and 14nm process nodes. In order to respond to increasing customer inquiries, Samsung plans to expand its automotive process nodes to 8nm in near future.
Samsung is also focusing on functional safety and component reliability, which are critically important in the automotive industry, since any failure could cause serious consequences of accident or injury.
Samsung has already proven its ability to design IPs to meet the required automotive standard, and received the ISO 26262 certification for functional safety in automotive components from TÜV Rheinland. Complying with reliability standard AEC-Q100 and IATF 16969 quality management system, it is also preparing for automotive semiconductor production.
Meanwhile, in cooperation with ecosystem partners, Samsung will host its first SAFETM (Samsung Advanced Foundry Ecosystem) Forum on Oct 17 in San Jose, to introduce Samsung's IP, Electronic Design Automation (EDA), and packaging solutions in detail for foundry partners.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005312/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
